Form 8-K - Current report:
SEC Accession No. 0001193125-25-158551
Filing Date
2025-07-14
Accepted
2025-07-14 11:13:05
Documents
13
Period of Report
2025-07-14
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d11473d8k.htm   iXBRL 8-K 35933
2 EX-99.1 d11473dex991.htm EX-99.1 9232
  Complete submission text file 0001193125-25-158551.txt   156486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA me-20250714.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE me-20250714_lab.xml EX-101.LAB 15957
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE me-20250714_pre.xml EX-101.PRE 9990
15 EXTRACTED XBRL INSTANCE DOCUMENT d11473d8k_htm.xml XML 3252
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 251120513
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)